EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated In Silico and Experimental Validation of Antrocin as a Plant-Derived Multi-Target Therapeutic for BRAF/MEK/PI3K-Driven Colorectal Cancer

Jian-Syun Chen iD, Chioma Grace Enwolo-Chibueze, Harold Arnold Chinyama, Cheng-Ta Lai, Ifeyinwa Chioma Ezeala, Po-Yang Huang, Alexander T H Wu iD, Yan-Jiun Huang

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26188780 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Jian-Syun Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Colon and Rectal Surgery, Department of Surgery, MacKay Memorial Hospital, Taipei 104217, Taiwan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Colorectal Neoplasms, Phosphatidylinositol 3-Kinases, Lactones. Die Arbeit nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) remains a leading cause of cancer-related death worldwide, with resistance to targeted therapies presenting a significant clinical challenge. This study combines computational and experimental methods to identify and validate Antrocin, a natural sesquiterpene lactone, as a potential multi-target inhibitor of the BRAF/MEK/PI3K oncogenic pathway in CRC. Differential gene expression and mutational analyses were performed using public datasets (TCGA, TNMplot, GEPIA2, GSCA, PANDA, and cBioPortal) to assess the prevalence and clinical significance of BRAF, MEK, and PI3K alterations in CRC. In silico molecular docking, using AutoDock Vina, predicted strong binding affinities of Antrocin to BRAF (ΔG = −8.5 kcal/mol), MEK (ΔG = −7.3 kcal/mol), and PI3K (ΔG = −6.9 kcal/mol), comparable to those of FDA-approved inhibitors for BRAF (Dabrafenib), MEK (Trametinib), and PI3K (Alpelisib). Drug-likeness and ADME properties were evaluated via SwissADME and ADMETlab, supporting Antrocin’s potential as a drug candidate. In vitro assays using HCT116 and RKO CRC cell lines validated that Antrocin treatment suppressed cell viability, spheroid formation, and migration, accompanied by reduced expression levels of the oncogenic BRAF/MEK/PI3K signaling pathway. Antrocin-treated tumor-conditioned medium experiments demonstrated Antrocin’s ability to reduce the differentiation of cancer-associated fibroblasts and the polarization of M2 macrophages. Preclinical mouse xenograft experiments demonstrated a delay in tumor growth following treatment with Antrocin. These results suggest that Antrocin, identified through computational screening and validated experimentally, could be a promising multi-target agent to overcome therapy resistance in CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafColorectal NeoplasmsPhosphatidylinositol 3-KinasesLactonesSesquiterpenesHumansAnimalsMiceMolecular Docking SimulationCell Line, TumorXenograft Model Antitumor AssaysSignal TransductionCell Proliferation

Stichwörter der Autor:innen

AntrocinBRAF/MEK/PI3K oncogenic signaturebioinformaticscolorectal cancer (CRC)drug resistancemulti-target therapy

Substanzen

Proto-Oncogene Proteins B-rafPhosphatidylinositol 3-KinasesBRAF protein, humanLactonesSesquiterpenes

Autor:innen und Institutionen

  • Division of Colon and Rectal Surgery, Department of Surgery, MacKay Memorial Hospital, Taipei 104217, Taiwan.
  • Department of Medicine, MacKay Medical University, New Taipei City 252005, Taiwan.
  • Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
  • Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
  • Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria Nsukka, Nsukka 410001, Nigeria.
  • The Ph.D. Program of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.

ORCID-Profile: Jian-Syun Chen, Alexander T H Wu

Förderung

  • National Science and Technology Council, Taiwan

Zitieren

APA

Chen, J. S., Enwolo-Chibueze, C. G., Chinyama, H. A., Lai, C. T., Ezeala, I. C., Huang, P. Y., Wu, A. T. H., & Huang, Y. J. (2025). Integrated In Silico and Experimental Validation of Antrocin as a Plant-Derived Multi-Target Therapeutic for BRAF/MEK/PI3K-Driven Colorectal Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26188780

Vancouver

Chen JS, Enwolo-Chibueze CG, Chinyama HA, Lai CT, Ezeala IC, Huang PY, et al. Integrated In Silico and Experimental Validation of Antrocin as a Plant-Derived Multi-Target Therapeutic for BRAF/MEK/PI3K-Driven Colorectal Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26188780

BibTeX
@article{Chen2025,
  author = {Chen, Jian-Syun and Enwolo-Chibueze, Chioma Grace and Chinyama, Harold Arnold and Lai, Cheng-Ta and Ezeala, Ifeyinwa Chioma and Huang, Po-Yang and Wu, Alexander T H and Huang, Yan-Jiun},
  title = {Integrated In Silico and Experimental Validation of Antrocin as a Plant-Derived Multi-Target Therapeutic for BRAF/MEK/PI3K-Driven Colorectal Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26188780}
}
Kostenlos starten →